STAND (Shortening Treatment by Advancing Novel Drugs) Trial

by | Apr 8, 2021 | Uncategorised

The Infection and Global Health Division are committed to finding new and better treatment for tuberculosis (TB) through high quality clinical trials.  Our work continues to test regimens including the novel drug pretomanid, developed by the TB Alliance.  We participated in their recent global STAND (Shortening Treatment by Advancing Novel Drugs) trial that included sites from across Africa, the Far East and Ukraine, and treated participants with pulmonary drug-susceptible TB (DS-TB).  We compared a regimen consisting of pyrazinamide, moxifloxacin and pretomanid for four months with the standard WHO DS-TB  regimen for six months.    The paper has now been published in the International Journal of Tuberculosis and Lung Diseases: https://www.ingentaconnect.com/contentone/iuatld/ijtld/2021/00000025/00000004/art00009.

The same team are continuing to evaluate novel pretomanid regimens through the SimpliciTB  (Simplified Short Treatment for Tuberculosis) trial.